The Filing Desk

Core Laboratories

CLB · NYSE · Energy · Financials, fiscal 2021 to 2025

CLB · Last close · November 13, 2026
$9.11
Value Core Laboratories yourself

Core Laboratories' revenue rose 0.5% to $526 million in fiscal 2025. Its operating margin was 10.7%, down from 11.2% a year earlier. Free cash flow was $26 million, down 42.0%. It paid out $14 million in dividends and buybacks, 55% of free cash flow. The diluted share count fell 1.4%.

CORE LABORATORIES INC. Latest fiscal year ended December 31, 2025 10-K filed March 23, 2026 · 0001193125-26-118177 Updated
Revenue
$526M
0.5%
Operating margin
10.7%
0.5 pts
Net income
$30M
5.5%
Free cash flow
$26M
42.0%
Return on capital
10.3%
0.7 pts
Market cap
$425M
Nov 13 close
P/E
26.8x
On $0.34 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Core Laboratories does

Core Laboratories sells measurement services and products to oil and gas companies. Its labs study reservoir rock and fluids such as crude oil, natural gas and water, so clients can judge how a field performs and recover more oil and gas. It also helps clients evaluate underground sites for carbon capture and storage. Its clients are mostly major, national and independent oil companies.

It reports two segments. Reservoir Description covers lab analysis of rocks and fluids, field services, studies and the lab equipment it makes. Production Enhancement covers products and services for well completions, perforating, stimulation and well abandonment, including perforating products it makes. Revenue comes from these services and product sales, mainly to the oil and gas industry.

Core Lab was established in 1936. It has over 70 offices in more than 50 countries and approximately 3,300 employees. In 2023 it changed its home from the Netherlands to Delaware through a redomestication.

Its biggest risks, as it describes them

  • Falling spending by oil and gas companies in downturns, which lowers demand for its services.
  • Conflict in the Middle East, where it owns and runs several laboratories.
  • Risks of doing business in many countries, since it relies on its international operations.
  • Cost-cutting steps that could disrupt operations or delay new products.
  • Holding too much unneeded inventory if it misjudges what clients will order.
From Core Laboratories's annual report on Form 10-K, filed March 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2021 to 2025, earnings per share grew 10.7% a year and net income 10.8% a year, as new shares raised the share count by 1% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1815151923
Debt incl. finance leases—175166128113
Net debt (negative means net cash)—16015110990
Net debt to EBITDA—2.7x2.1x1.5x1.3x
Debt to equity—0.9x0.7x0.5x0.4x
Interest coverage5.0x3.6x4.1x4.7x5.3x
Current ratio—2.0x2.5x2.2x2.0x
Quick ratio—1.5x1.7x1.6x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Core Laboratories' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $53,900 of Core Laboratories shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 31, 2026Lawrence BrunoChairman and CEO, DirectorBought5,000$10.78$53,900Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 95 of 97 of 9
Rule of 406.9%11.2%5.4%
Altman Z''3.463.613.75
Accruals ratio2.0%−4.3%−1.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassPass
Current ratio rosePassFailFail
Share count didn't riseFailFailPass
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score7 of 95 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Core Laboratories side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Core LaboratoriesFY250.5%10.7%4.9%10.3%1.3x7
Ranger Energy ServicesFY25−4.2%2.8%7.8%3.8%0.1x4Compare
Solaris Energy InfrastructureFY2598.7%21.8%−70.3%14.1%−0.8x—Compare
TETRA TechnologiesFY255.3%8.8%3.1%6.8%1.3x5Compare
Oil States InternationalFY25−3.4%−14.6%11.1%−12.4%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue470490510524526
Revenue growth—4.1%4.1%2.8%0.5%
Gross profit—96110103109
Research and development—————
Operating income4542555956
Net income2020373130
Diluted EPS (US$)0.420.420.770.660.63
Diluted shares (millions)4747484847
Cash flow
Cash from operations3725255637
Capital expenditure1410111211
Free cash flow2315144426
Dividends paid22222
Share buybacks842512
Acquisitions00001
Stock-based compensation1981447
Balance sheet at fiscal year end
Cash and short-term investments1815151923
Debt incl. finance leases—175166128113
Total assets581578586585584
Total liabilities—395362333312
Shareholders' equity161184225247266
Margins and ratios
Gross margin—19.6%21.5%19.7%20.7%
Operating margin9.6%8.5%10.7%11.2%10.7%
Net margin4.2%4.0%7.2%6.0%5.6%
Free cash flow margin4.9%3.0%2.8%8.5%4.9%
Rule of 40 (growth + FCF margin)—7.2%6.9%11.2%5.4%
Return on capital——13.7%11.1%10.3%
Return on equity—11.3%17.9%13.3%11.6%
Return on assets—3.4%6.3%5.4%5.1%
Net debt to EBITDA—2.7x2.1x1.5x1.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Core Laboratories' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Core Laboratories.